Vancomycin versus linezolid in the treatment of methicillin-resistant staphylococcus aureus nosocomial pneumonia: Implications of the ZEPHyR trial

Annals of Pharmacotherapy

Volumn 46, Issue 10, 2012, Pages 1432-1435

  Alaniz, Cesar ^a   Pogue, Jason M ^b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b SINAI GRACE HOSPITAL   (United States)

Author keywords

Linezolid; Pneumonia; Vancomycin

Indexed keywords

LINEZOLID; VANCOMYCIN;

ARTICLE; ARTIFICIAL VENTILATION; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VENTILATOR ASSOCIATED PNEUMONIA;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; VANCOMYCIN;

EID: 84867801809     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R221     Document Type: Article

References (19)

1. Rubinstein E, Cammarata SK, Oliphant TH, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001;32:402-12.
2. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus van-comycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003;25:980-92.
3. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: an analysis of two double-blind studies of pa-tients with methicillin-resistant Staphylococcus aureus nosocomial pneu-monia. Chest 2003;124:1789-97.
4. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in gram-positive ventilator-associated pneu-monia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004;30:388-94.
5. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother 1996;38:865-9.
6. Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharma-cokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475-80.
7. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416.
8. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methi-cillin-resistant Staphylococcus aureus nosocomial pneumonia: a random-ized controlled trial. Clin Infect Dis 2012;54:621-9.
9. Choi EY, Huh JW, Lim CH, et al. Relationship between the MIC of van-comycin and clinical outcome in patients with MRSA nosocomial pneu-monia. Intensive Care Med 2011;37:639-47.
10. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methi-cillin-resistant Staphylococcus aureus hospital-acquired, ventilator-asso-ciated, or health-care associated pneumonia. Chest 2010;138:1356-62.
11. Magret M, Lisboa T, Martin-Loaches I, et al. Bacteremia is an indepen-dent risk factor for mortality in nosocomial pneumonia: a prospective and observational multi-center study. Crit Care 2011;15:R62.
12. Kullar R, Davis SL, Levine D, Rybak MJ. Impact of vancomycin expo-sure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011;52:975-81.
13. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Soci-ety of Health System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Disease Pharmacists. Am J Health Sys Pharm 2009;66:82-98.
14. Pea F, Furlanut M, Cojutti P, et al. Therapeutic drug monitoring of line-zolid: a retrospective, monocentric analysis. Antimicrob Agents Chemother 2010;54:4605-10.
15. Kallen AJ, Mu Y, Bulens S, et al. Healthcare-associated invasive MRSA infections, 2005-2008. JAMA 2010;304:641-8.
16. Garcia MS, De La Torre MA, Morales G, et al. Clinical outbreak of line-zolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 2010;303:2260-4.
17. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin mini-mum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
18. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin resistant Staphylococ-cus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315-20.
19. Choi EY, Huh JW, Lim C, et al. Relationship between the MIC of van-comycin and clinical outcome in patients with MRSA nosocomial pneu-monia. Int Care Med 2011;37:639-47.